Evaluation of efficacy and safety of daclatasvir and sofosbuvir in treatment of chronic hepatitis C infection

Introduction The era of direct-acting analogs in the management of chronic hepatitis C virus (HCV) infection stared in 2011, and since then, many agents were approved for management of HCV infection. Aim To assess the efficacy and safety of daclatasvir and sofosbuvir in the treatment of chronic hepatitis C infection. Patients and methods A prospective study was done at El-Rajhi University Hospital. It included 100 patients (75 patients with chronic HCV infection and 25 patients with HCV-related compensated liver cirrhosis). They received dual therapy (sofosbuvir 400 mg plus daclatasvir 60 mg) for 12 weeks or 24 weeks for patients with chronic hepatitis C and patients with liver cirrhosis, respectively. Results Mean age of all patients was 51.48 ± 10.90 years. Overall, 64% were males, 52% were from rural areas, and 56% patients were unemployed. Sustained virological response (SVR) 12 was obtained in 98 (98%) patients included in our study, and only two (2%) patients failed to achieve sustained virological response: one patient had chronic hepatitis but took irregular course of therapy, whereas the other was a cirrhotic patient. It was noticed that 69 (69%) patients had no adverse effects during the course of therapy. Headache was the most frequent event occurred in 17 (17%) patients, comprising seven (9.3%) patients with chronic hepatitis C and 10 (40%) patients with liver cirrhosis. Conclusion This regimen of therapy has high success rate for viral eradication with minimal tolerable adverse effects.